Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 7, 2001, Pages 1972-1976

  Dietze, R ^a   Teixeira, L ^a   Canedo Rocha, L M ^a   Palaci, M ^a   Johnson, J L ^a   Wells, C ^a   Rose, L ^a   Eisenach, K ^a   Ellner, J J ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFALAZIL; RIFAMPICIN; RIFAMYCIN DERIVATIVE;

ADULT; ARTHRALGIA; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SPUTUM SMEAR; VERTIGO;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; FEMALE; HEMATOLOGIC TESTS; HUMANS; ISONIAZID; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MALE; RIFAMYCINS; TUBERCULOSIS, PULMONARY;

EID: 0034955967     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.7.1972-1976.2001     Document Type: Article

References (22)

1. Drug treatment of pulmonary tuberculosis
2. Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear positive tuberculosis
3. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy
4. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease
5. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis
6. Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs
7. HIV protease inhibitors, saquinavir, indinavir and ritonavir: Inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes
8. The early bactericidal activity of drugs in patients with pulmonary tuberculosis
9. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model
10. Effect of a new rifamycin derivative, rifalazil, on liver microssomal enzyme induction in rat and dog
11. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis
12. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids
13. Safety and pharmacokinetics of PA-1648 a new rifamycin in normal volunteers
14. Rapid radiometric tests to detect and differentiate Mycobacterium tuberculosis and Mycobacterium bovis from other mycobacterial species
15. Radiometric (BACTEC) tests for slow growing mycobacteria
16. Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore
17. Leucopenia caused by two rifampicin preparations
18. Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: A determinant of outcome in pulmonary tuberculosis treatment
19. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis
20. Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay